GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (BSP:N1BI34) » Definitions » Shiller PE Ratio

Neurocrine Biosciences (BSP:N1BI34) Shiller PE Ratio : 132.35 (As of May. 10, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Neurocrine Biosciences Shiller PE Ratio?

As of today (2025-05-10), Neurocrine Biosciences's current share price is R$34.41. Neurocrine Biosciences's E10 for the quarter that ended in Dec. 2024 was R$0.26. Neurocrine Biosciences's Shiller PE Ratio for today is 132.35.

The historical rank and industry rank for Neurocrine Biosciences's Shiller PE Ratio or its related term are showing as below:

BSP:N1BI34' s Shiller PE Ratio Range Over the Past 10 Years
Min: 104.45   Med: 330.78   Max: 10477
Current: 134.64

During the past years, Neurocrine Biosciences's highest Shiller PE Ratio was 10477.00. The lowest was 104.45. And the median was 330.78.

BSP:N1BI34's Shiller PE Ratio is ranked worse than
95.99% of 524 companies
in the Drug Manufacturers industry
Industry Median: 24.34 vs BSP:N1BI34: 134.64

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Neurocrine Biosciences's adjusted earnings per share data for the three months ended in Dec. 2024 was R$0.305. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is R$0.26 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Neurocrine Biosciences Shiller PE Ratio Historical Data

The historical data trend for Neurocrine Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Shiller PE Ratio Chart

Neurocrine Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1,770.24 328.27 160.18

Neurocrine Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 328.27 291.49 244.67 160.81 160.18

Competitive Comparison of Neurocrine Biosciences's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Shiller PE Ratio falls into.


;
;

Neurocrine Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Neurocrine Biosciences's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=34.41/0.26
=132.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Neurocrine Biosciences's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.305/133.1571*133.1571
=0.305

Current CPI (Dec. 2024) = 133.1571.

Neurocrine Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.002 99.621 -0.003
201506 -0.044 100.684 -0.058
201509 -0.078 100.392 -0.103
201512 -0.066 99.792 -0.088
201603 -0.041 100.470 -0.054
201606 -0.079 101.688 -0.103
201609 -0.070 101.861 -0.092
201612 -0.086 101.863 -0.112
201703 -0.141 102.862 -0.183
201706 -0.112 103.349 -0.144
201709 -0.020 104.136 -0.026
201712 0.012 104.011 0.015
201803 -0.077 105.290 -0.097
201806 -0.013 106.317 -0.016
201809 0.107 106.507 0.134
201812 0.037 105.998 0.046
201903 -0.215 107.251 -0.267
201906 0.104 108.070 0.128
201909 0.115 108.329 0.141
201912 0.072 108.420 0.088
202003 0.095 108.902 0.116
202006 0.210 108.767 0.257
202009 -0.167 109.815 -0.202
202012 0.921 109.897 1.116
202103 0.093 111.754 0.111
202106 0.108 114.631 0.125
202109 0.061 115.734 0.070
202112 -0.023 117.630 -0.026
202203 0.035 121.301 0.038
202206 -0.045 125.017 -0.048
202209 0.181 125.227 0.192
202212 0.231 125.222 0.246
202303 -0.206 127.348 -0.215
202306 0.231 128.729 0.239
202309 0.202 129.860 0.207
202312 0.353 129.419 0.363
202403 0.105 131.776 0.106
202406 0.170 132.554 0.171
202409 0.343 133.029 0.343
202412 0.305 133.157 0.305

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Neurocrine Biosciences  (BSP:N1BI34) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Neurocrine Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences Business Description

Traded in Other Exchanges
Address
6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Neurocrine Biosciences Headlines

No Headlines